Why the study?
Do topical NSAIDs improve outcomes in patients undergoing cataract surgery?
Do topical NSAIDs improve outcomes in patients undergoing cataract surgery?
Topical NSAIDs are discussed for their role in inhibiting prostaglandin biosynthesis and managing intraocular inflammation during cataract surgery.
Highlights role of topical NSAIDs for post-cataract inflammation; leaves open effects on visual outcomes.
Prostaglandins ARE 20-carbon metabolites of arachidonic acid that are biosynthesized by ocular tissues and are involved in human intraocular inflammation.1They are released in response to ocular trauma, including surgery.2When released in large concentrations following trauma, intraocular surgery, or in association with uveitis, they may contribute to the disruption of the blood-aqueous barrier, miosis, and cystoid macular edema (CME). By inhibiting the cyclooxygenase pathway of prostaglandin biosynthesis, a major metabolic pathway of arachidonic acid, nonsteroidal antiinflammatory drugs (NSAIDs) may be useful in patients undergoing cataract surgery.3Inhibitors of the lipoxygenase pathway, another major pathway of arachidonic acid metabolism, also are being evaluated. The US Food and Drug Administration (FDA) has approved several topical NSAIDs, each primarily a cyclooxygenase inhibitor, for clinical use in ophthalmology, but these approvals have been limited solely to specific indications. For example, flurbiprofen sodium (Ocufen) and suprofen (Profenal) are only approved for
No takes yet. Share an insight, caveat, or question.
Lee M. Jampol (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: